RTKs can activate Ras, a protein that is tethered to the plasma membrane, by causing it to bind GTP. Once activated, Ras can do a variety of things. In this example, it activates an enzymatic ...

Thus, we will focus primarily on the therapeutic targeting of the major RAS effector pathways, in addition to several essential co-opted pathways, as reviewed in the next section. MEK/CDK4 PD ...

The R&A has announced the qualification pathways for The 153rd Open at Royal Portrush, taking place July 13-20, 2025. The ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Cotargeting other parallel pathways would be justified if they are ... the nearly 3.4 million patients who receive a diagnosis of RAS-mutant cancer each year.

"Our findings represent a breakthrough in the treatment of HCM in children, particularly those suffering from severe forms of the disease due to genetic variants in the RAS/MAPK pathway," said ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and ...

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven cancers, ...